Why the study?
Does subcutaneous enoxaparin reduce bleeding complications while maintaining efficacy compared to acenocoumarol in elderly patients (>75 years) with proximal deep venous thrombosis?
Population
100 consecutive elderly patients with venographically demonstrated proximal deep venous thrombosis…
Comparison
Subcutaneous enoxaparin 4000 anti-Xa units once… vs Oral acenocoumarol for 3 months.
Design
RCT, randomly allocated on the eighth day
Follow-up
1 year
Authors
Loading...
No significant differences in VTE recurrence or bleeding support routine use of enoxaparin over acenocoumarol; leaves open LMWH monotherapy in elderly DVT.
Does subcutaneous enoxaparin reduce bleeding complications while maintaining efficacy compared to acenocoumarol in elderly patients (>75 years) with proximal deep venous thrombosis?
In elderly patients with proximal DVT, 3 months of enoxaparin showed similar efficacy to acenocoumarol with a trend toward fewer bleeding complications, though wide confidence intervals limit definitive conclusions.
Escribá et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: